公开(公告)号：US11197913B2

公开(公告)日：2021-12-14

申请号：US16993556

申请日：2020-08-14

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K39/395 ,  C07K16/24 ,  A61K38/20 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US10765724B2

公开(公告)日：2020-09-08

申请号：US15471790

申请日：2017-03-28

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K38/20 ,  A61K39/395 ,  C07K16/24 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US20180036379A1

公开(公告)日：2018-02-08

申请号：US15471790

申请日：2017-03-28

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K38/20 ,  C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A01K67/027 ,  C07K14/54

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.